ReviewFrontiers in endocrinology2020
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology.
Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients.BMC cancer · 2024Pooled it
- Prolactin and pain of endometriosis.Pharmacology & therapeutics · 2023Pooled it
- Pilot Study on the Effects of First-Line Antituberculosis Drugs and Their Combinations on Selected Reproductive Endpoints in Female Rats.Life (Basel, Switzerland) · 2026Article
- Cancer-like Hallmarks of Endometriosis: The Role of Estrogen Signaling and Stem Cell Plasticity.International journal of molecular sciences · 2026Review
- Protective Effects of Adenosine Triphosphate and Flunarizine on Erlotinib-Induced Ovarian Damage: An Experimental Study.Life (Basel, Switzerland) · 2026Article
- Article
- Preclinical Effect of Shaofu Zhuyu Decoction on Decidualization and the Expression of PR-β and HNRNPL in a Mouse Model of Endometriosis-Associated Infertility.Drug design, development and therapy · 2026Article
- Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis.Signal transduction and targeted therapy · 2025Article
- Artificial intelligence-derived retinal age gap as a marker for reproductive aging in women.NPJ digital medicine · 2025Article
- Stress-Induced Hyperprolactinemia Mimicking Pituitary Pathology: A Diagnostic Challenge.Cureus · 2025Article
- CART Neurons in the Hypothalamic Ventral Premammillary Nucleus (PMv) in Rats Mediate Maternal, But Not Inter-male Aggression.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Suppression of hypothalamic oestrogenic signal sustains hyperprolactinemia and metabolic adaptation in lactating mice.Nature metabolism · 2025Article
- Elevated prolactin levels before endometrial transformation negatively impact reproductive outcomes in frozen embryo transfer cycles under hormone replacement therapy.BMC pregnancy and childbirth · 2025Article
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Pro-fertility andProtein and peptide letters · 2025Article
- Prolactin and Hyperprolactinaemia in Endometriosis-Related Infertility: Are There Clinically Significant Connections?Journal of clinical medicine · 2024Review
- Serum anti-mullerian hormone, sex hormone, and nutrient levels in reproductive age women with celiac disease.Journal of assisted reproduction and genetics · 2024Article
- Current Insights in Prolactin Signaling and Ovulatory Function.International journal of molecular sciences · 2024Review
- Article
- Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last years, increasing evidence has focused on crucial pathogenetic role of PRL on malignant, premalignant and benign uterine diseases. Studies in animals and humans have documented that PRL receptors (PRL-Rs) are widely expressed on uterine cells and that PRL is directly synthesized by the endometrium under the stimulatory action of progesterone. Uterine PRL secretion is finely modulated by autocrine/paracrine mechanisms which do not depend on the same control factors implied in the regulation of PRL secretion from pituitary. On the other hand, PRL is synthesized also in the myometrium and directly promotes uterine smooth muscle cell growth and proliferation. Therefore, PRL and PRL-Rs appear to play an important role for the activation of signaling pathways involved in uterine cancers and preneoplastic lesions. Circulating PRL levels are reportedly increased in patients with cervical or endometrial cancers, as well as uterine premalignant lesions, and might be used as discriminative biomarker in patients with uterine cancers. Similarly, increased PRL levels have been implicated in the endometriosis-induced infertility, albeit a clear a causative role for PRL in the pathogenesis of endometriosis is yet to be demonstrated. This evidence has suggested the potential application of dopamine agonists in the therapeutic algorithm of women with malignant, premalignant and benign uterine lesions. This review focuses on the role of PRL as tumorigenic factor for uterus and the outcome of medical treatment with dopamine agonists in patients with malignant and benign uterine disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.